Impact of Human Immunodeficiency Virus in the Pathogenesis and Outcome of Patients with Glioblastoma Multiforme

다국어 초록 (Multilingual Abstract)

Background Improvement in antiviral therapies have been accompanied by an increased frequency of non-Acquired Immune Deficiency Syndrome (AIDS) defining malignancies, such as glioblastoma multiforme. Here, we investigated all reported cases of human immunodeficiency virus (HIV)-positive patients with glioblastoma and evaluated their clinical outcomes. A comprehensive review of the molecular pathogenetic mechanisms underlying glioblastoma development in the setting of HIV/AIDS is provided.
Methods We performed a PubMed search using keywords “HIV glioma” AND “glioblastoma,” and “AIDS glioma” AND “glioblastoma.” Case reports and series describing HIV-positive patients with glioblastoma (histologically-proven World Health Organization grade IV astrocytoma) and reporting on HAART treatment status, clinical follow-up, and overall survival (OS), were included for the purposes of quantitative synthesis. Patients without clinical follow-up data or OS were excluded. Remaining articles were assessed for data extraction eligibility.
Results A total of 17 patients met our inclusion criteria. Of these patients, 14 (82.4%) were male and 3 (17.6%) were female, with a mean age of 39.5±9.2 years (range 19–60 years). Average CD4 count at diagnosis of glioblastoma was 358.9±193.4 cells/mm3. Tumor progression rather than AIDS-associated complications dictated patient survival. There was a trend towards increased median survival with HAART treatment (12.0 vs 7.5 months, p=0.10) Conclusion Our data suggests that HAART is associated with improved survival in patients with HIV-associated glioblastoma, although the precise mechanisms underlying this improvement remain unclear.

참고문헌 (Reference)

1 Jain V, "When to start antiretroviral therapy" 7 : 60-68, 2010

2 Vajkoczy P, "Vascular microenvironment in gliomas" 50 : 99-108, 2000

3 Sinkovics JG, "Vaccination against human cancers (review)" 16 : 81-96, 2000

4 Carmeliet P, "VEGF as a key mediator of angiogenesis in cancer" 69 (69): 4-10, 2005

5 Monfardini S, "Unusual malignant tumours in 49 patients with HIV infection" 3 : 449-452, 1989

6 de Vos AF, "Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs" 169 : 5415-5423, 2002

7 Rossi ML, "The mononuclear cell infiltrate compared with survival in high-grade astrocytomas" 78 : 189-193, 1989

8 Góngora-Rivera F, "The clinical spectrum of neurological manifestations in AIDS patients in Mexico" 31 : 393-398, 2000

9 Walker PR, "The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells" 165 : 3128-3135, 2000

10 Kim CM, "The HIV tat gene transforms human keratinocytes" 7 : 1525-1529, 1992

11 Vogel J, "The HIV tat gene induces dermal lesions resembling Kaposi’s sarcoma in transgenic mice" 335 : 606-611, 1988

12 Hickey WF, "T-lymphocyte entry into the central nervous system" 28 : 254-260, 1991

13 Kohleisen B, "Stable expression of HIV-1Nef induces changes in growth properties and activation state of human astrocytes" 13 : 2331-2341, 1999

14 Pore N, "Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism" 15 : 4841-4853, 2004

15 Briggs SD, "SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1" 272 : 17899-17902, 1997

16 Groom HC, "Rev regulates translation of human immunodeficiency virus type 1 RNAs" 90 (90): 1141-1147, 2009

17 Kjems J, "Rev protein and its cellular partners" 48 : 251-298, 2000

18 Autran B, "Restoration of the immune system with anti-retroviral therapy" 66 : 207-211, 1999

19 Powderly WG, "Recovery of the immune system with antiretroviral therapy: the end of opportunism?" 280 : 72-77, 1998

20 Selmaj KW, "Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor" 144 : 129-135, 1990

21 Safdari H, "Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas" 23 : 221-226, 1985

22 Blumenthal DT, "Primary intracranial neoplasms in patients with HIV" 52 : 1648-1651, 1999

23 Bayraktar S, "Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors" 101 : 257-265, 2011

24 Felber BK, "Posttranscriptional control of HIV-1 and other retroviruses and its practical applications" 55 : 161-197, 2007

25 Ohgaki H, "Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas" 64 : 479-489, 2005

26 Dal Maso L, "Pattern of cancer risk in persons with AIDS in Italy in the HAART era" 100 : 840-847, 2000

27 Geleziunas R, "Pathogenesis and therapy of HIV-1 infection of the central nervous system" 6 : 1411-1426, 1992

28 Radu A, "PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1" 23 : 6139-6149, 2003

29 Struss AK, "PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme" 20 : 4107-4114, 2001

30 Hajjar M, "Non-acquired immune deficiency syndrome-defining malignancies in a hospital-based cohort of human immunodeficiency virus-infected patients: Bordeaux, France, 1985-1991. Groupe d’Epidémiologie Clinique du SIDA en Aquitaine" 84 : 1593-1595, 1992

31 Rosenblum ML, "Neurosurgical implications of the acquired immunodeficiency syndrome (AIDS)" 34 : 419-445, 1988

32 Petito CK, "Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review" 45 : 635-646, 1986

33 Basić-Jukić N, "Neurological complications in renal transplant recipients" 62 (62): 76-81, 2008

34 Simpson DM, "Neurologic manifestations of HIV infection" 121 : 769-785, 1994

35 Power C, "NeuroAIDS: an evolving epidemic" 36 : 285-295, 2009

36 Pore N, "Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy" 66 : 9252-9259, 2006

37 Palella FJ Jr, "Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study" 43 : 27-34, 2006

38 Böker DK, "Mononuclear infiltrates in human intracranial tumors as a prognostic factor. Influence of preoperative steroid treatment. I. Glioblastoma" 3 : 143-147, 1984

39 Zhong H, "Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics" 60 : 1541-1545, 2000

40 Aloisi F, "Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation" 160 : 4671-4680, 1998

41 Hall JR, "Management of glioblastoma multiforme in HIV patients: a case series and review of published studies" 21 : 591-597, 2009

42 Weill O, "Malignant spinal cord glioma. A new complication of HIV virus infection?" 16 : 1977-, 1987

43 Platten M, "Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape" 52 : 401-410, 2001

44 Wahl SM, "Macrophage- and astrocyte-derived transforming growth factor beta as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome" 173 : 981-991, 1991

45 Palma L, "Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases" 49 : 854-861, 1978

46 Zundel W, "Loss of PTEN facilitates HIF-1-mediated gene expression" 14 : 391-396, 2000

47 Krex D, "Long-term survival with glioblastoma multiforme" 130 (130): 2596-2606, 2007

48 Lawson HC, "Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience" 83 : 61-70, 2007

49 Brack-Werner R, "Infection of human brain cells by HIV-1: restricted virus production in chronically infected human glial cell lines" 6 : 273-285, 1992

50 Hiesse C, "Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients" 27 : 972-974, 1995

51 Shelburne SA, "Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy" 19 : 399-406, 2005

52 Lohse N, "Improved survival in HIVinfected persons: consequences and perspectives" 60 : 461-463, 2007

53 Plettenberg A, "Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS" 39 : 3-12, 2011

54 Prins RM, "Immunology and immunotherapy in neurosurgical disease" 53 : 144-152, 2003

55 Barker CF, "Immunologically privileged sites" 25 : 1-54, 1977

56 Martin D, "Immune restoration in the context of HAART" 5 : 8-14, 2004

57 Corbeau P, "Immune reconstitution under antiretroviral therapy:the new challenge in HIV-1 infection" 117 : 5582-5590, 2011

58 Wang J, "Immune reconstitution of acquired immune deficiency syndrome" 16 : 557-564, 2010

59 Guihot A, "Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus" 32 : 131-137, 2011

60 Wiemels JL, "IgE, allergy, and risk of glioma:update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era" 125 : 680-687, 2009

61 Du Z, "Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys" 82 : 665-674, 1995

62 Wu AH, "Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas" 76 : 23-30, 2006

63 Calzascia T, "Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs" 22 : 175-184, 2005

64 Harrington M, "Hit HIV-1 hard, but only when necessary" 355 : 2147-2152, 2000

65 Wiemels JL, "History of allergies among adults with glioma and controls" 98 : 609-615, 2002

66 Aboulafia DM, "Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment" 21 : 900-907, 2007

67 Wiendl H, "Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells" 13 : 343-351, 2003

68 Xia C, "HIV-associated dementia in the era of highly active antiretroviral therapy (HAART)" 13 : 419-425, 2011

69 Kramer-Hämmerle S, "HIV type 1Nef promotes neoplastic transformation of immortalized neural cells" 17 : 597-602, 2001

70 Pore N, "HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells" 8 : 889-895, 2006

71 Gupta AK, "HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo" 65 : 8256-8265, 2005

72 Liu G, "HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells" 64 : 4980-4986, 2004

73 UNAIDS, "Global report: UNAIDS report on the global AIDS epidemic 2010"

74 Chamberlain MC, "Gliomas in patients with acquired immune deficiency syndrome" 74 : 1912-1914, 1994

75 Schiff D, "Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation?" 57 : 1486-1488, 2001

76 Wolff R, "Glioblastoma multiforme of the brain stem in a patient with acquired immunodeficiency syndrome" 144 : 941-944, 2002

77 Vannemreddy PS, "Glioblastoma multiforme in a case of acquired immunodeficiency syndrome:investigation a possible oncogenic influence of human immunodeficiency virus on glial cells. Case report and review of the literature" 92 : 161-164, 2000

78 Salvati M, "Glioblastoma in kidney transplant recipients. Report of five cases" 63 : 33-37, 2003

79 Ohgaki H, "Genetic pathways to glioblastoma:a population-based study" 64 : 6892-6899, 2004

80 Dunn GP, "Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma" 7 : 12-, 2007

81 Laurent N, "Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo" 3 : 129-136, 2004

82 Kennedy BC, "Dynamics of central and peripheral immunomodulation in a murine glioma model" 10 : 11-, 2009

83 Palella FJ Jr, "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators" 338 : 853-860, 1998

84 Kushen MC, "Current immunotherapeutic strategies for central nervous system tumors" 16 : 987-1004, 2007

85 Vincendeau M, "Control of HIV replication in astrocytes by a family of highly conserved host proteins with a common Rev-interacting domain (Risp)" 24 : 2433-2442, 2012

86 Moyle G, "Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity" 22 : 911-936, 2000

87 Cserr HF, "Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view" 13 : 507-512, 1992

88 Waubant E, "Cervical cord glioma in an HIV-positive patient" 39 : 58-60, 1998

89 Moulignier A, "Cerebral glial tumors and human immunodeficiency virus-1 infection. More than a coincidental association" 74 : 686-692, 1994

90 Gasnault J, "Cerebral astrocytoma in association with HIV infection" 51 : 422-424, 1988

91 Gervasoni C, "Cerebral astrocytoma in HIV-infected patients" 9 : 403-404, 1995

92 Wiley CA, "Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients" 83 : 7089-7093, 1986

93 Leone S, "Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort" 39 : 13-20, 2011

94 Yang I, "CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival" 17 : 1381-1385, 2010

95 Liu Y, "CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor" 78 : 4120-4133, 2004

96 Perrin G, "Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset" 11 : 1337-1350, 1999

97 Carrana EJ, "Anaplastic astrocytoma in association with human immunodeficiency virus type 1 infection" 8 : 565-567, 1990

98 Schiffer D, "Analysis of some factors effecting survival in malignant gliomas" 65 : 119-125, 1979

99 Cusimano MD, "An update on the cellular and molecular biology of brain tumors" 16 : 22-27, 1989

100 Walker PR, "All in the head: obstacles for immune rejection of brain tumours" 107 : 28-38, 2002

101 Pore N, "Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway" 4 : 471-479, 2006

102 Tacconi L, "Acquired immune deficiency syndrome (AIDS) and cerebral astrocytoma" 98 : 149-151, 1996

103 Shiels MS, "A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals" 52 : 611-622, 2009

104 Neal JW, "A malignant astrocytoma in a patient with AIDS: a possible association between astrocytomas and HIV infection" 33 : 159-162, 1996

105 Wiendl H, "A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape" 168 : 4772-4780, 2002